Abstract
The c-myb gene encodes a transcription factor that is central to hematopoietic cell growth. Phosphorylation of c-Myb by casein kinase 2 (CK2) at serines 11 and 12 has been variously implicated in the regulation of DNA binding. However, it is unclear when c-Myb phosphorylation at serines 11 and 12 occurs during the cell cycle and how this is regulated. We generated specific antisera that recognize phosphoserines 11 and 12 of c-Myb. C-Myb protein levels, extent of CK2 phosphorylation and DNA binding were then monitored following mitogenic stimulus and passage through the cell cycle in normal peripheral T-cells and the T leukemia cell line CCRF-CEM. We found that endogenous c-Myb is constitutively phosphorylated at serines 11 and 12. The amount of phosphorylated c-Myb correlates with DNA binding activity in cycling CEM cells but not upon entry of T-cells into the cell cycle. Exogenous expression of c-Myb with substitutions of serines 11 and 12 with glutamic acid or alanine had no effect on the transactivation of a c-Myb responsive reporter. These data strongly suggest that c-Myb is constitutively phosphorylated on serines 11 and 12 by CK2 or like activity and is not regulated during the cell cycle.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Allen III RD, Bender TP, Siu G . 1999 Genes Dev. 13: 1073–1078
Badiani P, Corbella P, Kioussis D, Marvel J, Weston K . 1994 Genes Dev. 8: 770–782
Bender TP, Thompson CB, Kuehl WM . 1987 Science 237: 1473–1476
Bies J, Feikova S, Bottaro DP, Wolff L . 2000 Oncogene 19: 2846–2854
Darzynkiewicz Z, Traganos F, Sharpless T, Melamed MR . 1976 Proc. Natl. Acad. Sci. USA 73: 2881–2884
Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, McCarthy RE . 1965 Cancer 18: 522–529
Gewirtz AM, Anfossi G, Venturelli D, Valpreda S, Sims R, Calabretta B . 1989 Science 245: 180–183
Golay J, Capucci A, Arsura M, Castellano M, Rizzo V, Introna M . 1991 Blood 77: 149–158
Hodges RS, Merrifield RB . 1975 Anal. Biochem. 65: 241–272
Kauffman MG, Noga SJ, Kelly TJ, Donnenberg AD . 1990 Anal. Biochem. 191: 41–46
Lam MH, House CM, Tiganis T, Mitchelhill KI, Sarcevic B, Cures A, Ramsay R, Kemp BE, Martin TJ, Gillespie MT . 1999 J. Biol. Chem. 274: 18559–18566
Lipsick S, Boyle WJ . 1987 Mol. Cell Biol. 7: 3358–3360
Luscher B, Christenson E, Litchfield DW, Krebs EG, Eisenman RN . 1990 Nature 344: 517–522
McCarthy RE, Junius V, Farber S, Lazarus H, Foley GE . 1965 Exp. Cell Res. 40: 197–200
Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, Miller TA, Pietryga DW, Scott Jr WJ, Potter SS . 1991 Cell 65: 677–689
Nakagoshi H, Nagase T, Ueno Y, Ishii S . 1989 Nucleic Acids Res. 17: 7315–7324
Ness SA . 1996 Biochim. Biophys. Acta. 1288: F123–F139
Nishina Y, Nakagoshi H, Imamoto F, Gonda TJ, Ishii S . 1989 Nucleic Acids Res. 17: 107–117
Nomura T, Sakai N, Sarai A, Sudo T, Kanei-Ishii C, Ramsay RG, Favier D, Gonda TJ, Ishii S . 1993 J. Biol. Chem. 268: 21914–21923
Norman MR, Thompson EB . 1977 Cancer Res. 37: 3785–3791
Oh IH, Reddy EP . 1999 Oncogene 18: 3017–3033
Pearson RB, Mitchelhill KI, Kemp BE . 1993 Protein Phosphorylation–a Practical Approach Oxford University Press, New York
Pines J . 1994 Semin. Cancer Biol. 5: 305–313
Ramsay RG . 1995 Meth. Mol. Biol. 37: 369–377
Ramsay RG, Ishii S, Nishina Y, Soe G, Gonda TJ . 1989 Oncogene Res. 4: 259–269
Ramsay RG, Morrice N, Van Eeden P, Kanagasundaram V, Nomura T, De Blaquiere J, Ishii S, Wettenhall R . 1995 Oncogene 11: 2113–2120
Sakura H, Kanei-Ishii C, Nagase T, Nakagoshi H, Gonda TJ, Ishii S . 1989 Proc. Natl. Acad. Sci. USA 86: 5758–5762
Sala A, Casella I, Grasso L, Bellon T, Reed JC, Miyashita T, Peschle C . 1996 Cancer Res. 56: 1991–1996
Slamon DJ, Boone TC, Murdock DC, Keith DE, Press MF, Larson RA, Souza LM . 1986 Science 233: 347–351
Slamon DJ, deKernion JB, Verma IM, Cline MJ . 1984 Science 224: 256–262
Taylor D, Badiani P, Weston K . 1996 Genes Dev. 10: 2732–2744
Thompson CB, Challoner PB, Neiman PE, Groudine M . 1986 Nature 319: 374–380
Thompson MA, Flegg R, Westin EH, Ramsay RG . 1997 Oncogene 14: 1715–1723
Tiganis T, House CM, Kemp BE . 1993 Biochim. Biophys. Acta. 1203: 282–289
Venturelli D, Travali S, Calabretta B . 1990 Proc. Natl. Acad. Sci. USA 87: 5963–5967
Watson RJ . 1988 Mol. Cell Biol. 8: 3938–3942
Weston K . 1998 Curr. Opin. Genet. Dev. 8: 76–81
Zorbas M, Sicurella C, Bertoncello I, Venter D, Ellis S, Mucenski ML, Ramsay RG . 1999 Oncogene 18: 5821–5830
Acknowledgements
Many thanks to Ralph Rossi for help with the FACS analysis. Ms Ruth Freeman and Ms Selma Stuffrein provided expert research assistance. We also want to thank Dr Kathy Weston for providing us with the dominant negative Myb constructs and Dr Maree Overall for critical reading of the manuscript. RG Ramsay and R Kemp are NHMRC fellows.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cures, A., House, C., Kanei-Ishii, C. et al. Constitutive c-Myb amino-terminal phosphorylation and DNA binding activity uncoupled during entry and passage through the cell cycle. Oncogene 20, 1784–1792 (2001). https://doi.org/10.1038/sj.onc.1204345
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204345
Keywords
This article is cited by
-
Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways
Leukemia (2012)
-
MYB function in normal and cancer cells
Nature Reviews Cancer (2008)
-
c-Myb
AfCS-Nature Molecule Pages (2006)
-
Casein kinase II alpha 1
AfCS-Nature Molecule Pages (2006)